68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?

Wien Med Wochenschr. 2019 Feb;169(1-2):3-11. doi: 10.1007/s10354-017-0569-z. Epub 2017 Jun 2.

Abstract

Ever since the introduction of 68Ga-prostate-specific membrane antigen 11 positron-emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) a few years ago, it has rapidly achieved great success in the field of prostate cancer imaging. A large number of studies have been published to date, indicating a high potential of 68Ga-PSMA-11 PET/CT in the work-up of prostate cancer patients, including primary diagnosis, staging and biochemical recurrence. The aim of this review is to present the most important data on this novel, highly promising imaging technique, and to formulate recommendations for possible applications of 68Ga-PSMA-11 PET/CT in clinical routine.

Keywords: 68Ga-PSMA-11 PET/CT; Biochemical recurrence; Indication; Prostate cancer; Staging.

Publication types

  • Review

MeSH terms

  • Edetic Acid / administration & dosage
  • Edetic Acid / analogs & derivatives
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Male
  • Neoplasm Grading
  • Nuclear Medicine*
  • Oligopeptides / administration & dosage
  • Positron Emission Tomography Computed Tomography / methods*
  • Prostatic Neoplasms* / diagnostic imaging
  • Radiopharmaceuticals

Substances

  • Gallium Isotopes
  • Gallium Radioisotopes
  • Oligopeptides
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • Edetic Acid